{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:40:23Z","timestamp":1784072423727,"version":"3.55.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.amjmed.2023.09.015","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:33:45Z","timestamp":1697060025000},"page":"12-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Controversies in Hypertension V: Resistant and Refractory Hypertension"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3161-5820","authenticated-orcid":false,"given":"Edward J.","family":"Filippone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald V.","family":"Naccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Foy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.amjmed.2023.09.015_bib0001","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.amjmed.2023.09.015_bib0002","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11906-022-01185-6","article-title":"An update on refractory hypertension","volume":"24","author":"Matanes","year":"2022","journal-title":"Curr Hypertens Rep"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.015_bib0003","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1161\/HYPERTENSIONAHA.119.14137","article-title":"Antihypertensive medication adherence and confirmation of true refractory hypertension","volume":"75","author":"Siddiqui","year":"2020","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.015_bib0004","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.015_bib0005","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jash.2016.03.186","article-title":"Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement","volume":"10","author":"Bhatt","year":"2016","journal-title":"J Am Soc Hypertens"},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.015_bib0006","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jamacardio.2023.0720","article-title":"Efficacy and safety of low-dose triple and quadruple combination pills vs monotherapy, usual care, or placebo for the initial management of hypertension: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.amjmed.2023.09.015_bib0007","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","article-title":"Fixed-dose combinations improve medication compliance: a meta-analysis","volume":"120","author":"Bangalore","year":"2007","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2023.09.015_bib0008","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/HYPERTENSIONAHA.113.01448","article-title":"Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network","volume":"62","author":"Egan","year":"2013","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.015_bib0009","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jash.2013.06.004","article-title":"Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence","volume":"7","author":"Grigoryan","year":"2013","journal-title":"J Am Soc Hypertens"},{"issue":"12","key":"10.1016\/j.amjmed.2023.09.015_bib0010","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0895-7061(01)02193-8","article-title":"Is resistant hypertension really resistant?","volume":"14","author":"Brown","year":"2001","journal-title":"Am J Hypertens"},{"issue":"5","key":"10.1016\/j.amjmed.2023.09.015_bib0011","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring","volume":"57","author":"de la","year":"2011","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.amjmed.2023.09.015_bib0012","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.amjhyper.2005.05.014","article-title":"Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension","volume":"18","author":"Pierdomenico","year":"2005","journal-title":"Am J Hypertens"},{"issue":"12","key":"10.1016\/j.amjmed.2023.09.015_bib0013","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007365","article-title":"Prevalence and clinical characteristics of refractory hypertension","volume":"6","author":"Armario","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"17","key":"10.1016\/j.amjmed.2023.09.015_bib0014","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017634","article-title":"Refractory hypertension and risks of adverse cardiovascular events and mortality in patients with resistant hypertension: a prospective cohort study","volume":"9","author":"Cardoso","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.015_bib0015","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/01.HYP.31.2.712","article-title":"Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study","volume":"31","author":"Redon","year":"1998","journal-title":"Hypertension"},{"issue":"21","key":"10.1016\/j.amjmed.2023.09.015_bib0016","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/archinte.168.21.2340","article-title":"Prognostic influence of office and ambulatory blood pressures in resistant hypertension","volume":"168","author":"Salles","year":"2008","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.015_bib0017","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/HYPERTENSIONAHA.116.07464","article-title":"Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension","volume":"68","author":"Berra","year":"2016","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.amjmed.2023.09.015_bib0018","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/08037051.2015.1121706","article-title":"Adherence to medication and drug monitoring in apparent treatment-resistant hypertension","volume":"25","author":"Esk\u00e5s","year":"2016","journal-title":"Blood Press"},{"issue":"4","key":"10.1016\/j.amjmed.2023.09.015_bib0019","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/HJH.0000000000002294","article-title":"Medication adherence in hypertension","volume":"38","author":"Poulter","year":"2020","journal-title":"J Hypertens"},{"issue":"9","key":"10.1016\/j.amjmed.2023.09.015_bib0020","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/HJH.0000000000003492","article-title":"A practical approach to assessment of non-adherence to antihypertensive treatment","volume":"41","author":"Kocianova","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjmed.2023.09.015_bib0021","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1471-2288-11-149","article-title":"Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review","volume":"11","author":"Garfield","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.amjmed.2023.09.015_bib0022","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/1472-6963-12-270","article-title":"Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss","volume":"12","author":"Meddings","year":"2012","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"10.1016\/j.amjmed.2023.09.015_bib0023","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/08037051.2017.1346458","article-title":"Heart rate is a useful marker of adherence to beta-blocker treatment in hypertension","volume":"26","author":"Koci\u00e1nov\u00e1","year":"2017","journal-title":"Blood Press"},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.015_bib0024","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jash.2015.04.004","article-title":"Comparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatment-resistant hypertension","volume":"9","author":"Pandey","year":"2015","journal-title":"J Am Soc Hypertens"},{"issue":"5","key":"10.1016\/j.amjmed.2023.09.015_bib0025","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/HJH.0000000000000503","article-title":"Are two commonly used self-report questionnaires useful for identifying antihypertensive medication nonadherence?","volume":"33","author":"Gallagher","year":"2015","journal-title":"J Hypertens"},{"issue":"8","key":"10.1016\/j.amjmed.2023.09.015_bib0026","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pds.1230","article-title":"Methods for evaluation of medication adherence and persistence using automated databases","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.015_bib0027","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/bcp.12942","article-title":"A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence","volume":"82","author":"El Alili","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.015_bib0028","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/jhh.2010.108","article-title":"How common is true resistant hypertension?","volume":"25","author":"Bunker","year":"2011","journal-title":"J Hum Hypertens"},{"issue":"3","key":"10.1016\/j.amjmed.2023.09.015_bib0029","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/HYPERTENSIONAHA.113.01452","article-title":"Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure","volume":"62","author":"Fadl Elmula","year":"2013","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.amjmed.2023.09.015_bib0030","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/HYPERTENSIONAHA.114.03246","article-title":"Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension","volume":"63","author":"Fadl Elmula","year":"2014","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.015_bib0031","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/jhh.2015.38","article-title":"Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic","volume":"30","author":"Hameed","year":"2016","journal-title":"J Hum Hypertens"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.015_bib0032","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1109\/TBME.2014.2341272","article-title":"An ingestible sensor for measuring medication adherence","volume":"62","author":"Hafezi","year":"2015","journal-title":"IEEE Trans Biomed Eng"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.015_bib0033","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/hr.2010.183","article-title":"Difficult-to-control arterial hypertension or uncooperative patients? the assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy","volume":"34","author":"Ceral","year":"2011","journal-title":"Hypertens Res"},{"issue":"12","key":"10.1016\/j.amjmed.2023.09.015_bib0034","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1097\/HJH.0b013e3283652c61","article-title":"Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis","volume":"31","author":"Strauch","year":"2013","journal-title":"J Hypertens"},{"issue":"4","key":"10.1016\/j.amjmed.2023.09.015_bib0035","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","article-title":"Resistant hypertension? Assessment of adherence by toxicological urine analysis","volume":"31","author":"Jung","year":"2013","journal-title":"J Hypertens"},{"issue":"8","key":"10.1016\/j.amjmed.2023.09.015_bib0036","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jacc.2013.10.067","article-title":"Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension","volume":"63","author":"Brinker","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.amjmed.2023.09.015_bib0037","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/heartjnl-2013-305063","article-title":"High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS\/MS) urine analysis","volume":"100","author":"Tomaszewski","year":"2014","journal-title":"Heart"},{"issue":"1-2","key":"10.1016\/j.amjmed.2023.09.015_bib0038","doi-asserted-by":"crossref","first-page":"65","DOI":"10.20452\/pamw.2648","article-title":"Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis. A subgroup evaluation of the RESIST-POL study","volume":"125","author":"Florczak","year":"2015","journal-title":"Pol Arch Med Wewn"},{"issue":"12","key":"10.1016\/j.amjmed.2023.09.015_bib0039","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00392-015-0905-5","article-title":"Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine\/plasma toxicological analysis","volume":"104","author":"Ewen","year":"2015","journal-title":"Clin Res Cardiol"},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.015_bib0040","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/jhh.2015.103","article-title":"Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation","volume":"30","author":"Patel","year":"2016","journal-title":"J Hum Hypertens"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.015_bib0041","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002343","article-title":"Adherence to antihypertensive medication in treatment-resistant hypertension undergoing renal denervation","volume":"5","author":"Schmieder","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.amjmed.2023.09.015_bib0042","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1097\/HJH.0000000000001402","article-title":"Routine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patients","volume":"35","author":"Hamdidouche","year":"2017","journal-title":"J Hypertens"},{"issue":"4","key":"10.1016\/j.amjmed.2023.09.015_bib0043","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/jhh.2016.69","article-title":"Detecting non-adherence by urine analysis in patients with uncontrolled hypertension: rates, reasons and reactions","volume":"31","author":"Pucci","year":"2017","journal-title":"J Hum Hypertens"},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.015_bib0044","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1161\/HYPERTENSIONAHA.116.08729","article-title":"Risk factors for nonadherence to antihypertensive treatment","volume":"69","author":"Gupta","year":"2017","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.015_bib0045","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/08037051.2021.2004087","article-title":"Adherence to antihypertensive drug treatment in kidney transplant recipients","volume":"30","author":"Georges","year":"2021","journal-title":"Blood Press"},{"issue":"8","key":"10.1016\/j.amjmed.2023.09.015_bib0046","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/HJH.0000000000003459","article-title":"Monitoring antihypertensive drug concentrations to determine nonadherence in hypertensive patients with or without a kidney transplant","volume":"41","author":"Peeters","year":"2023","journal-title":"J Hypertens"},{"issue":"5","key":"10.1016\/j.amjmed.2023.09.015_bib0047","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/HYPERTENSIONAHA.117.09631","article-title":"Biochemical screening for nonadherence is associated with blood pressure reduction and improvement in adherence","volume":"70","author":"Gupta","year":"2017","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.amjmed.2023.09.015_bib0048","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/jhh.2013.140","article-title":"Apparent and true resistant hypertension: Definition, prevalence and outcomes","volume":"28","author":"Judd","year":"2014","journal-title":"J Hum Hypertens"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.015_bib0049","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.015_bib0050","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/HYPERTENSIONAHA.118.12191","article-title":"Prevalence of apparent treatment-resistant hypertension in the united states","volume":"73","author":"Carey","year":"2019","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.amjmed.2023.09.015_bib0051","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1111\/jch.14043","article-title":"Prevalence and prognosis of the 2018 vs 2008 AHA definitions of apparent treatment-resistant hypertension in high-risk hypertension patients","volume":"22","author":"Chun","year":"2020","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"9","key":"10.1016\/j.amjmed.2023.09.015_bib0052","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/HYPERTENSIONAHA.123.20894","article-title":"Characterization of individuals with apparent resistant hypertension using contemporary guidelines: insights from CV-QUIC","volume":"80","author":"Ebinger","year":"2023","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.amjmed.2023.09.015_bib0053","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.ejim.2012.04.012","article-title":"Resistant hypertension in visceral obesity","volume":"23","author":"Holecki","year":"2012","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.amjmed.2023.09.015_bib0054","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/340929","article-title":"Resistant hypertension and obstructive sleep apnea in the primary-care setting","volume":"2011","author":"Demede","year":"2011","journal-title":"Int J Hypertens"},{"issue":"10","key":"10.1016\/j.amjmed.2023.09.015_bib0055","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/jch.12410","article-title":"Resistant hypertension and associated comorbidities in a veterans affairs population","volume":"16","author":"Acharya","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.015_bib0056","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.ajkd.2020.04.017","article-title":"Resistant hypertension in people with CKD: a review","volume":"77","author":"Fay","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.015_bib0057","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/HYPERTENSIONAHA.120.15064","article-title":"Adverse health outcomes associated with refractory and treatment-resistant hypertension in the chronic renal insufficiency cohort","volume":"77","author":"Buhnerkempe","year":"2021","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.amjmed.2023.09.015_bib0058","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1097\/00004872-200111000-00018","article-title":"High prevalence of cardiac and extracardiac target organ damage in refractory hypertension","volume":"19","author":"Cuspidi","year":"2001","journal-title":"J Hypertens"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.015_bib0059","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/jhh.2009.35","article-title":"Urinary albumin excretion is associated with true resistant hypertension","volume":"24","author":"Oliveras","year":"2010","journal-title":"J Hum Hypertens"},{"issue":"13","key":"10.1016\/j.amjmed.2023.09.015_bib0060","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.amjmed.2023.09.015_bib0061","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11906-022-01165-w","article-title":"Refractory hypertension: a narrative systematic review with emphasis on prognosis","volume":"24","author":"Bacan","year":"2022","journal-title":"Curr Hypertens Rep"},{"issue":"5","key":"10.1016\/j.amjmed.2023.09.015_bib0062","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1161\/01.HYP.0000016176.16042.2F","article-title":"Resistant hypertension: comparing hemodynamic management to specialist care","volume":"39","author":"Taler","year":"2002","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.015_bib0063","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.015_bib0064","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"Hyperaldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.amjmed.2023.09.015_bib0065","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","article-title":"Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion","volume":"168","author":"Gaddam","year":"2008","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.amjmed.2023.09.015_bib0066","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.015_bib0067","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/HYPERTENSIONAHA.115.05449","article-title":"Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure","volume":"66","author":"Dudenbostel","year":"2015","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.015_bib0068","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/HYPERTENSIONAHA.118.10965","article-title":"Refractory hypertension is not attributable to intravascular fluid retention as determined by intracardiac volumes","volume":"72","author":"Velasco","year":"2018","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.amjmed.2023.09.015_bib0069","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/ajh\/hpv031","article-title":"The effects of aldosterone antagonists in patients with resistant hypertension: A meta-analysis of randomized and nonrandomized studies","volume":"28","author":"Dahal","year":"2015","journal-title":"Am J Hypertens"},{"issue":"5","key":"10.1016\/j.amjmed.2023.09.015_bib0070","first-page":"7270","article-title":"Clinical efficacy of spironolactone for resistant hypertension: a meta analysis from randomized controlled clinical trials","volume":"8","author":"Guo","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"3","key":"10.1016\/j.amjmed.2023.09.015_bib0071","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/jhh.2014.64","article-title":"Effect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis","volume":"29","author":"Liu","year":"2015","journal-title":"J Hum Hypertens"},{"issue":"10008","key":"10.1016\/j.amjmed.2023.09.015_bib0072","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.amjmed.2023.09.015_bib0073","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/2047487316675194","article-title":"Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: a systematic review and meta-analysis","volume":"24","author":"Sinnott","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"10.1016\/j.amjmed.2023.09.015_bib0074","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. randomized Aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.amjmed.2023.09.015_bib0075","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.amjmed.2023.09.015_bib0076","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.amjmed.2023.09.015_bib0077","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the randomized double-blind reminder study","volume":"35","author":"Montalescot","year":"2014","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.amjmed.2023.09.015_bib0078","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial","volume":"67","author":"Beygui","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.amjmed.2023.09.015_bib0079","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/HJH.0000000000002187","article-title":"Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Alexandrou","year":"2019","journal-title":"J Hypertens"},{"issue":"4","key":"10.1016\/j.amjmed.2023.09.015_bib0080","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.015_bib0081","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"10","key":"10.1016\/j.amjmed.2023.09.015_bib0082","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"10003","key":"10.1016\/j.amjmed.2023.09.015_bib0083","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/S0140-6736(15)00418-3","article-title":"The double challenge of resistant hypertension and chronic kidney disease","volume":"386","author":"Rossignol","year":"2015","journal-title":"Lancet"},{"issue":"10208","key":"10.1016\/j.amjmed.2023.09.015_bib0084","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.amjmed.2023.09.015_bib0085","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.2215\/CJN.02890221","article-title":"Patiromer to enable spironolactone in patients with resistant hypertension and CKD (AMBER): results in the prespecified subgroup with diabetes","volume":"16","author":"Agarwal","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.amjmed.2023.09.015_bib0086","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ejhf.1860","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjmed.2023.09.015_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2023.109291","article-title":"Molecular pharmacology of mineralocorticoid receptor antagonists: the role of co-regulators","volume":"199","author":"Koca","year":"2023","journal-title":"Steroids"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.015_bib0088","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.amjmed.2023.09.015_bib0089","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/ndt\/gfac322","article-title":"Non-steroidal mineralocorticoid receptor antagonists and cardiorenal outcomes in chronic kidney disease","volume":"38","author":"Lo","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.amjmed.2023.09.015_bib0090","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41371-019-0207-x","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study","volume":"33","author":"Ito","year":"2019","journal-title":"J Hum Hypertens"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.015_bib0091","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2023.09.015_bib0092","doi-asserted-by":"crossref","DOI":"10.1093\/ajh\/hpad066","article-title":"Efficacy and safety of ocedurenone: subgroup analysis of the BLOCK-CKD study","author":"Bakris","year":"2023","journal-title":"Am J Hypertens"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.015_bib0093","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2022","journal-title":"Clin Kidney J"},{"issue":"31","key":"10.1016\/j.amjmed.2023.09.015_bib0094","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.amjmed.2023.09.015_bib0095","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.amjmed.2023.09.015_bib0096","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J Diabetes Complications"},{"issue":"8","key":"10.1016\/j.amjmed.2023.09.015_bib0097","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.amjmed.2023.09.015_bib0098","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"23","key":"10.1016\/j.amjmed.2023.09.015_bib0099","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.amjmed.2023.09.015_bib0100","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.015_bib0101","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.amjmed.2023.09.015_bib0102","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2215\/CJN.0000000000000149","article-title":"Outcomes with finerenone in participants with stage 4 CKD and type 2 diabetes: a FIDELITY subgroup analysis","volume":"18","author":"Sarafidis","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2023.09.015_bib0103","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.amjcard.2022.12.032","article-title":"A subgroup meta-analysis comparing the renal denervation sham-controlled randomized trials among those with resistant and nonresistant hypertension","volume":"191","author":"Ahmed","year":"2023","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.amjmed.2023.09.015_bib0104","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/ajh\/hpaa042","article-title":"Reserpine substantially lowers blood pressure in patients with refractory hypertension: a proof-of-concept study","volume":"33","author":"Siddiqui","year":"2020","journal-title":"Am J Hypertens"},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.015_bib0105","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1097\/HJH.0000000000002053","article-title":"Effect of continuous positive airway pressure in patients with true refractory hypertension and sleep apnea: a post-hoc intention-to-treat analysis of the HIPARCO randomized clinical trial","volume":"37","author":"Navarro-Soriano","year":"2019","journal-title":"J Hypertens"},{"issue":"2","key":"10.1016\/j.amjmed.2023.09.015_bib0106","doi-asserted-by":"crossref","first-page":"54","DOI":"10.18087\/cardio.2021.2.n1102","article-title":"Refractory and resistant hypertension in patients with type 2 diabetes mellitus: different response to renal denervation","volume":"61","author":"Falkovskaya","year":"2021","journal-title":"Kardiologiia"},{"issue":"1","key":"10.1016\/j.amjmed.2023.09.015_bib0107","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"issue":"11","key":"10.1016\/j.amjmed.2023.09.015_bib0108","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/13543784.2021.2002844","article-title":"Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics","volume":"30","author":"Barrera-Chimal","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"10.1016\/j.amjmed.2023.09.015_bib0109","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1053\/j.ajkd.2018.06.018","article-title":"Optimized reference intervals for plasma free metanephrines in patients with CKD","volume":"72","author":"Pamporaki","year":"2018","journal-title":"Am J Kidney Dis"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934323006186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934323006186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:31:59Z","timestamp":1757583119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934323006186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0002934323006186"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2023.09.015","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies in Hypertension V: Resistant and Refractory Hypertension","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2023.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}